At Tuesday's close, Cingulate shares fell 4.99% to $3.62 and slipped further 1.66% to $3.56 in after-hours trading. According to the Kansas-based biotech, children who took CTx-1301 at doses of 18 ...

Cingulate shares rose 8.7% to close at $4.25 on Tuesday but slipped 4.2% to $4.07 in after-hours trading. Following a pre-NDA meeting on April 2, the company confirmed that it will submit an NDA ...

It follows the announcement that Cingulate has been granted European Patent No. 3261625 for its flagship asset, CTx-1301, which is designed to treat Attention Deficit Hyperactivity Disorder (ADHD).

Activate your anterior cingulate cortex with a little meditation. ScienceDaily. Retrieved June 2, 2025 from www.sciencedaily.com / releases / 2013 / 06 / 130604114001.htm.

When we are hard at work, the anterior cingulate cortex located near the front of our brain tracks our efforts, and its neural activity appears to be associated with how bad the exertion feels.

KANSAS CITY, Kan., March 19, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery ...

The Kansas City, Kansas-based pharmaceutical startup has worked its way through a couple of delisting warnings from the Nasdaq stock exchange. Cingulate loses key execs, almost its entire board ...

KANSAS CITY, Kan., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug ...

The amygdala's neighbors in the brain include the anterior cingulate cortex, which neuroscientists think controls various so-called executive processes, such as deciding where attention should be ...